Nice work CJ.
Of course the other way to have gotten this info would have been from my post on Nov. 21 which stated:
“Interferon by itself as a monotherapy achieves only a 1.0-1.5 log reduction in viral load. When combined with Ribavirin this increases to 2.0 log reduction. Given that Bavi has no toxicity, if the repeat dose data comes in next month showing a reduction anywhere from 1.0-2.0 logs for Bavi as a monotherapy, Bavi will have earned a secure place in the pantheon of new HCV therapies.“
If I were posting merely a guess or my opinion, I would have said so.
Maybe you can also find independent confirmation that the load reduction increases to 2.0 log when Ribavirin is added to Interferon. In my IBG, Bavi will do quite well when Ribavirin is added to Bavi !!
As you and Jazz have explained so well, the Company is setting the stage for the public to understand that Bavi is about to become the immunotherapy of choice used in combination with various anti-viral therapies BECAUSE:
1. Bavi has no toxicity, Interferon has lots; and
2. Bavi’s MOA is so far upstream that it promotes dendritic cell activity and a lasting innate immune response. Interferon’s MOA doesn’t have the same advantage.
As SK said at the 10-24-06 SHM, Bavi could become “… a MAINSTREAM PRODUCT for combination therapy. And it should be noted that most chronic viral infections, as well as many acute viral infections, are treated as part of a combination therapy.”
My question is not “if” Bavi will become the SOC for background immunotherapy. Instead, I would like to know how big is the global interferon market that Bavi will replace. Can you get any info on that?
Thanks in advance. BOT
